PumaBiotech (@pumabiotech) / X
Puma Biotechnology Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics
PBYI Stock Price and Chart — NASDAQ:PBYI — TradingView
Puma Biotechnology, Inc. (NASD:PBYI) Seasonal Chart | Equity Clock
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor | Business Wire
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor | Business Wire
Puma Biotech (PBYI) Q4 Loss Wider Than Expected, Sales Top
PBYI Insider Trading Activity - Puma Biotechnology, Inc.
PUMA BIOTECHNOLOGY, INC. : Other Events (form 8-K) -December 16, 2022 at 04:18 pm EST | MarketScreener
PBYI - Puma Biotechnology Inc Stock - Stock Price, Institutional Ownership, Shareholders (NASDAQ)
Puma Biotechnology, Inc. - SEC Filings - Annual Reports & Proxies
Puma Biotechnology, Inc. 2023 Q2 - Results - Earnings Call Presentation (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Inc. Advanced Charts | PBYI | Barron's
Puma Biotechnology, Inc. | CDISC
Articles about Puma Biotechnology
PUMA BIOTECHNOLOGY, INC. FORM 8-K/A - Shareholder.com
PBYI Stock Price and Chart — NASDAQ:PBYI — TradingView
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
Puma Biotechnology, Inc. (NASD:PBYI) Seasonal Chart | Equity Clock
Puma Biotech agrees to pay investors $54.2 mln in fraud case | Reuters
Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News
Puma Biotechnology, Inc.
Praneeth C. - Senior Clinical Data Manager - Exelixis | LinkedIn
Puma Biotechnology (PBYI) - 5 Price Charts 2012-2023 (History)
